Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment

Halina Bartosik-Psujek; Monika Adamczyk-Sowa; Alina Kułakowska; Joanna Głażewska; Anna Smaga; Waldemar Brola

doi:10.5114/ppn.2023.129048

eISSN: 2720-5371
ISSN: 1230-2813

Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii

Current issue Archive Manuscripts accepted About the journal Scientific board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Without publication fees

Open access

2/2023
vol. 32

Send email

Copy url:

abstract:

Original paper

Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment

Halina Bartosik-Psujek

¹

,

Monika Adamczyk-Sowa

²

,

Alina Kułakowska

³

,

Joanna Głażewska

⁴

,

Anna Smaga

⁵

,

Waldemar Brola

⁶

Department of Neurology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszow, Poland
Department of Neurology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland
Department of Neurology, Medical University of Bialystok, Bialystok, Poland
PEX PharmaSequence, Warsaw, Poland
5National Institute of Public Health NIH – National Research Institute, Warsaw, Poland
Collegium Medicum, Jan Kochanowski University, Kielce, Poland

Adv Psychiatry Neurol 2023; 32 (2): 59–67

DOI: https://doi.org/10.5114/ppn.2023.129048

Online publish date: 2023/06/30

View full text Get citation

EndNote

Papers, Reference Manager, RefWorks, Zotero

AMA

Bartosik-Psujek H, Adamczyk-Sowa M, Kułakowska A, Głażewska J, Smaga A, Brola W. Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(2):59-67. doi:10.5114/ppn.2023.129048.

APA

Bartosik-Psujek, H., Adamczyk-Sowa, M., Kułakowska, A., Głażewska, J., Smaga, A.,  & Brola, W. (2023). Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(2), 59-67. https://doi.org/10.5114/ppn.2023.129048

Chicago

Bartosik-Psujek, Halina, Monika Adamczyk-Sowa, Alina Kułakowska, Joanna Głażewska, Anna Smaga,  and Waldemar Brola. 2023. "Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment". Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii 32 (2): 59-67. doi:10.5114/ppn.2023.129048.

Harvard

Bartosik-Psujek, H., Adamczyk-Sowa, M., Kułakowska, A., Głażewska, J., Smaga, A.,  and Brola, W. (2023). Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, 32(2), pp.59-67. https://doi.org/10.5114/ppn.2023.129048

MLA

Bartosik-Psujek, Halina et al. "Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment." Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii, vol. 32, no. 2, 2023, pp. 59-67. doi:10.5114/ppn.2023.129048.

Vancouver

Bartosik-Psujek H, Adamczyk-Sowa M, Kułakowska A, Głażewska J, Smaga A, Brola W. Course of therapy in patients with
active relapsing-remitting multiple
sclerosis despite first-line treatment. Advances in Psychiatry and Neurology/Postępy Psychiatrii i Neurologii. 2023;32(2):59-67. doi:10.5114/ppn.2023.129048.

PlumX metrics:

Purpose
Treatment of patients with relapsing-remitting multiple sclerosis (RRMS) in Poland begins with first-line therapy; however, the treatment often fails. The aim of this study was to investigate the course of first-line treatment in patients who, despite experiencing an active course of the disease, did not receive more efficacious treatment due to the existing criteria in the drug program.

Methods
The study included 139 patients from 45 treatment centers. Medical data concerning the course of treatment were collected with the use of specific forms.

Results
The most frequently used drugs were β-interferons, and treatment was initiated with these drugs in most cases; however, administration of dimethyl fumarate was also common. The median treatment duration was 30.9 months, with the longest treatment duration observed for β-interferons. The most common reason for therapy switching or termination was treatment failure.

Conclusions
First-line therapy in the studied population was based mainly on β-interferons and dimethyl fumarate. For most medications, the discontinuation of therapy or drug switching were very common and the main reason was total or partial treatment failure. These observations suggest the need for earlier implementation of more effective treatment, based on drugs with high efficacy, in the study population.

keywords:

Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment

Halina Bartosik-Psujek 1 , Monika Adamczyk-Sowa 2 , Alina Kułakowska 3 , Joanna Głażewska 4 , Anna Smaga 5 , Waldemar Brola 6

multiple sclerosis, first-line therapy, high-efficiency therapy

Halina Bartosik-Psujek

¹

,

Monika Adamczyk-Sowa

²

,

Alina Kułakowska

³

,

Joanna Głażewska

⁴

,

Anna Smaga

⁵

,

Waldemar Brola

⁶